Skip to main content
OpenTrials
Completed

NCT Number: NCT03970798

A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin

The purpose of this study is to evaluate the influence of repeated oral doses of KW-6356 on the pharmacokinetics of index substrates for CYP3A4/5, CYP1A2 and BCRP.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Parkinson's Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Movement Disorders Nervous System Diseases Neurodegenerative Diseases Parkinson Disease Parkinsonian Disorders Synucleinopathies

Age range

20 year–44 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Fukuoka Mirai Hospital Clinical Research Center

Fukuoka, Japan

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Individuals having issued written consent to this study at their own discretion
  • Japanese males aged 20 to 44 years at the time of informed consent
  • Body mass index (BMI) of 18.5 to <25.0 at screening
  • Resting pulse rate of 40 to 100 bpm, systolic blood pressure of 90 to 139 mmHg, and diastolic blood pressure of 40 to 89 mmHg when measured in the supine position at screening

Exclusion criteria

  • Individuals with any current disease requiring treatment
  • Individuals having drug allergy or its history
  • Individuals having psychiatric disease or its history
  • Positive results for any of the following infection-related items examined at screening: hepatitis B surface (HBs) antigen, HBs antibody, hepatitis B core (HBc) antibody, hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antigen/antibody, human T-lymphotropic virus (HTLV)-1 antibody, rapid plasma reagin (PRP) test, Treponema pallidum (TP) antibody.
  • Individuals with clinically significant abnormality detected on 12-lead electrocardiogram (ECG) recorded prior to the first dose of index substrate.
  • Individuals categorized as patients listed in the warnings or contraindications section of the package insert of any of the relevant index substrates (see separate protocol annex 6-8)
  • Individuals having used any drug (including over-the-counter [OTC] drugs, topical agents, vitamin preparations, health supplements, and Chinese herbal medicines) within 2 weeks prior to the first dose of index substrate.
  • Individuals having consumed grapefruit (including any food or beverage containing grapefruit) or any food or beverage containing St John's wort within 1 week prior to the first dose of index substrate.
  • Individuals having smoked or used smoking cessation agents (including chewing or eating of nicotine-containing products and application of nicotine patches) within 4 weeks prior to the first dose of index substrate.
  • Individuals having received inpatient treatment or surgery within 12 weeks prior to the first dose of index substrate.
  • Individuals having participated in a clinical study of a pharmaceutical product or a medical device or any equivalent study and used the investigational product or the unapproved medical device within 16 weeks prior to the first dose of index substrate.
  • Individuals having undergone collection of ≥400 mL of blood within 12 weeks prior to the first dose of index substrate or ≥200 mL of blood within 4 weeks prior to the first dose of index substrate (for blood donation or clinical trial, etc.) or pheresis donation (plateletpheresis or plasmapheresis donation) within 2 weeks prior to the first dose of index substrate.
  • Individuals having issued no consent to adoption of any appropriate contraceptive method during a period from day of admission to 12 weeks after the final dose of the study drug. The appropriate contraceptive method is defined as sexual abstinence or use of 2 of the following contraceptive devices: condom, oral contraceptives, intrauterine device, and pessary.
  • Individuals having received KW-6356 before.
  • Other individuals unsuitable for participating in the study in the opinion of the investigator or subinvestigator.

Treatment and study plan

midazolam

Drug

In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.

Caffeine

Drug

In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.

Rosuvastatin

Drug

In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.

KW-6356

Drug

In Period 2, Day 4-13(except Day11) a single dose of KW-6356 will be administered after breakfast, Day 11 a single dose of KW-6356 will be administered after fasting for at least 10 hours.

Primary outcomes

  1. Geometric mean ratio of the major pharmacokinetic parameter (AUC0-t) of the index substrates in combination with or without KW-6356

    Time frame: Starting around 2 hours before intake of the index substrates and continued until 24 hours after the last dose of KW-6356

Secondary outcomes

  1. Geometric mean ratio of the major pharmacokinetic parameters (Cmax) of the index substrates in combination with or without KW-6356

    Time frame: Starting around 2 hours before intake of the index substrates and continued until 24 hours after the last dose of KW-6356

  2. Geometric mean ratio of the major pharmacokinetic parameters (AUC0-∞) of the index substrates in combination with or without KW-6356

    Time frame: Starting around 2 hours before intake of the index substrates and continued until 24 hours after the last dose of KW-6356

  3. Pharmacokinetic parameters (tmax) of the index substrates

    Time frame: Starting around 2 hours before intake of the index substrates and continued until 24 hours after the last dose of KW-6356

  4. Pharmacokinetic parameters (CL/F) of the index substrates

    Time frame: Starting around 2 hours before intake of the index substrates and continued until 24 hours after the last dose of KW-6356

  5. Pharmacokinetic parameters (Vz/F) of the index substrates

    Time frame: Starting around 2 hours before intake of the index substrates and continued until 24 hours after the last dose of KW-6356

  6. Pharmacokinetic parameters (t1/2) of the index substrates

    Time frame: Starting around 2 hours before intake of the index substrates and continued until 24 hours after the last dose of KW-6356

  7. Plasma concentrations of the index substrates

    Time frame: Starting around 2 hours before intake of the index substrates and continued until 24 hours after the last dose of KW-6356

  8. Plasma concentrations of KW-6356

    Time frame: Starting around 2 hours before intake of KW-6356 and continued until 24 hours after the last dose of KW-6356

  9. Incidence of treatment-emergent adverse events

    Time frame: Starting 24 or 48 hours before intake of the index substrates and continued until 8 days after the last dose of KW-6356

Sponsors and collaborators

Lead sponsor

Kyowa Kirin Co., Ltd.

Industry

Registry information

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Jun 3, 2019
Registry last updated
Nov 29, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.